Skip to main content

Table 1 Baseline demographics and disease characteristics

From: A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study

  Arm 1
MTX or SSZ monotherapy
(n = 32)
Arm 2
Combo MTX+ 6 wks prednisone
(n = 32)
Arm 3
Combo MTX+ etanercept
(n = 30)
Age (years) 8.8 (4.8-12.7) 10.2 (6.6-13.9) 8.6 (4.2-12.4)
Symptom duration* (month) 7.8 (5.3-11.6) 5.9 (4.4-13.3) 8.5 (5.0-13.1)
ANA positive (%) 15 (47) 11 (34) 9 (30)
Female (%) 24 (75) 19 (59) 20 (67)
JIA category:    
Oligo (persistent)
Poly articular
Psoriatic (poly)
5 (3)
22
5
3 (1)
22
7
2 (2)
24
4
VAS physician (mm) 48 (40-55) 50 (39-58) 51 (37-61)
VAS patient/parent (mm) 48 (31-58) 59 (35-74) 58 (39-71)
CHAQ (0-3) 0.88 (0.28-1.50) 0.94 (0.63-1.69) 0.88 (0.75-1.53)
No. active joints 7.5 (5.0-12.5) 7.5 (6.0-11.8) 8.5 (5.8-13.0)
No. limited joints 2 (0-4.5) 2 (1.0-3.8) 3 (1.8-5.0)
ESR (mm/hour) 6.5 (2-11) 6.0 (2-24) 9.0 (4-25)
JADAS-10 (0-40) 15.7 (13.5-20.2) 17.9 (15.2-21.9) 19.1 (13.8-23.2)
  1. All results in medians (InterQuartile Range) unless stated otherwise;*time from first presenting symptoms to inclusion in the study